...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
Reply New Message
Back To Forum List View
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
7
LongRVXer
Mar 15, 2021 08:27AM
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
3
fuzzyjr
Mar 15, 2021 10:22AM

Thanks for posting LongRVXer. I will re-post as a press release (I am a little slow today).

BDAZ

4 Recommendations
Icon president Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
3
BearDownAZ
Mar 15, 2021 01:22PM
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
3
fuzzyjr
Mar 15, 2021 01:57PM
Icon president Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
8
BearDownAZ
Mar 15, 2021 09:53PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply